Seneca Biopharma Inc. [NASDAQ: SNCA] jumped around 0.16 points on Monday, while shares priced at $1.55 at the close of the session, up 11.51%. The company report on April 19, 2021 that Leading BioSciences Provides Update to Seneca Biopharma, Inc. Stockholders on Merger Closing Process Following Virtual Special Meeting on April 23, 2021 and Upcoming Milestones Following Planned Close of Merger.
Video message details merger closing process following completion of the April 23 virtual Special Meeting as well as next planned milestones for the merged company to be renamed Palisade Bio.
As of April 19, 2021, based on voting indications, Proposal 1 is expected to be approved at the Special Meeting completing the transaction.
Seneca Biopharma Inc. stock is now 76.14% up from its year-to-date (YTD) trading value. SNCA Stock saw the intraday high of $1.56 and lowest of $1.38 per share. The company’s 52-week high price is 2.67, which means current price is +78.16% above from all time high which was touched on 03/22/21.
Compared to the average trading volume of 3.75M shares, SNCA reached a trading volume of 1197545 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Seneca Biopharma Inc. [SNCA]?
The Average True Range (ATR) for Seneca Biopharma Inc. is set at 0.20, with the Price to Sales ratio for SNCA stock in the period of the last 12 months amounting to 2029.22. The Price to Book ratio for the last quarter was 2.77, with the Price to Cash per share for the same quarter was set at 0.59.
How has SNCA stock performed recently?
Seneca Biopharma Inc. [SNCA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.33. With this latest performance, SNCA shares dropped by -11.43% in over the last four-week period, additionally plugging by 131.38% over the last 6 months – not to mention a rise of 89.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNCA stock in for the last two-week period is set at 48.65, with the RSI for the last a single of trading hit 48.04, and the three-weeks RSI is set at 49.65 for Seneca Biopharma Inc. [SNCA]. The present Moving Average for the last 50 days of trading for this stock 1.5968, while it was recorded at 1.4720 for the last single week of trading, and 0.9916 for the last 200 days.
Seneca Biopharma Inc. [SNCA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Seneca Biopharma Inc. [SNCA] shares currently have an operating margin of -78961.14. Seneca Biopharma Inc.’s Net Margin is presently recorded at -120316.72.
Return on Total Capital for SNCA is now -141.63, given the latest momentum, and Return on Invested Capital for the company is -216.28. Return on Equity for this stock declined to -218.44, with Return on Assets sitting at -165.71.
Reflecting on the efficiency of the workforce at the company, Seneca Biopharma Inc. [SNCA] managed to generate an average of -$2,323,831 per employee. Receivables Turnover for the company is 0.20 with a Total Asset Turnover recorded at a value of 0.00.Seneca Biopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.00 and a Current Ratio set at 4.00.
Earnings analysis for Seneca Biopharma Inc. [SNCA]
With the latest financial reports released by the company, Seneca Biopharma Inc. posted -13/share EPS, while the average EPS was predicted by analysts to be reported at -9.1/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -42.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNCA.
Insider trade positions for Seneca Biopharma Inc. [SNCA]
There are presently around $1 million, or 12.90% of SNCA stock, in the hands of institutional investors. The top three institutional holders of SNCA stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 167,512, which is approximately -35.774% of the company’s market cap and around 0.81% of the total institutional ownership; VIRTU FINANCIAL LLC, holding 123,558 shares of the stock with an approximate value of $0.19 million in SNCA stocks shares; and HIGHTOWER ADVISORS, LLC, currently with $0.15 million in SNCA stock with ownership of nearly -33.354% of the company’s market capitalization.
Positions in Seneca Biopharma Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 10 institutional holders increased their position in Seneca Biopharma Inc. [NASDAQ:SNCA] by around 184,192 shares. Additionally, 4 investors decreased positions by around 536,906 shares, while 7 investors held positions by with 167,715 shares. The mentioned changes placed institutional holdings at 553,383 shares, according to the latest SEC report filing. SNCA stock had 4 new institutional investments in for a total of 55,412 shares, while 1 institutional investors sold positions of 393,411 shares during the same period.